133 related articles for article (PubMed ID: 12445178)
1. Hepatic graft-versus-host disease resembling acute hepatitis: additional treatment with ursodeoxycholic acid.
Chiba T; Yokosuka O; Kanda T; Fukai K; Imazeki F; Saisho H; Nishimura M; Saito Y
Liver; 2002 Dec; 22(6):514-7. PubMed ID: 12445178
[TBL] [Abstract][Full Text] [Related]
2. Hepatic GVHD after HLA-haploidentical bone marrow transplantation in children with severe combined immunodeficiency: the effect of ursodeoxycholic acid.
Wulffraat NM; Haddad E; Benkerrou M; Spliet WG; Patey N; Fischer A; de Graeff-Meeder BR
Br J Haematol; 1997 Mar; 96(4):776-80. PubMed ID: 9074421
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features in patients with hepatic graft-versus-host disease.
Chiba T; Yokosuka O; Goto S; Fukai K; Imazeki F; Kohno Y; Nishimura M; Saito Y; Saisho H
Hepatogastroenterology; 2005; 52(66):1849-53. PubMed ID: 16334791
[TBL] [Abstract][Full Text] [Related]
4. Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis.
Strasser SI; Shulman HM; Flowers ME; Reddy R; Margolis DA; Prumbaum M; Seropian SE; McDonald GB
Hepatology; 2000 Dec; 32(6):1265-71. PubMed ID: 11093733
[TBL] [Abstract][Full Text] [Related]
5. [Hypercholesterolemia as a part of chronic GVHD after allogeneic stem cell transplantation].
Koyama M; Matsuoka K; Kunisaki Y; Takeuchi M; Matsue K
Rinsho Ketsueki; 2004 Oct; 45(10):1115-8. PubMed ID: 15553047
[TBL] [Abstract][Full Text] [Related]
6. Chronic graft-versus-host disease of the liver presenting as an acute hepatitis following nonmyeloablative hematopoietic stem cell transplantation.
Maeng H; Lee JH; Cheong JW; Lee ST; Hahn JS; Ko YW; Min YH
Int J Hematol; 2004 Jun; 79(5):501-4. PubMed ID: 15239404
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
[TBL] [Abstract][Full Text] [Related]
9. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial.
Essell JH; Schroeder MT; Harman GS; Halvorson R; Lew V; Callander N; Snyder M; Lewis SK; Allerton JP; Thompson JM
Ann Intern Med; 1998 Jun; 128(12 Pt 1):975-81. PubMed ID: 9625683
[TBL] [Abstract][Full Text] [Related]
10. Chronic graft-versus-host disease complicated by acute hepatitis B.
Chiba T; Yokosuka O; Kojima H; Fukai K; Imazeki F; Saisho H; Nishimura M; Saito Y
J Clin Gastroenterol; 2003 Feb; 36(2):179-81. PubMed ID: 12544205
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid in the treatment of liver diseases.
Saksena S; Tandon RK
Postgrad Med J; 1997 Feb; 73(856):75-80. PubMed ID: 9122101
[TBL] [Abstract][Full Text] [Related]
12. Nephrotic syndrome as a clinical manifestation of graft-versus-host disease (GVHD) in a marrow transplant recipient after cyclosporine withdrawal.
Oliveira JS; Bahia D; Franco M; Balda C; Stella S; Kerbauy J
Bone Marrow Transplant; 1999 Jan; 23(1):99-101. PubMed ID: 10037059
[TBL] [Abstract][Full Text] [Related]
13. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
Lebensztejn DM
Med Sci Monit; 2000; 6(3):632-6. PubMed ID: 11208384
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver.
Fried RH; Murakami CS; Fisher LD; Willson RA; Sullivan KM; McDonald GB
Ann Intern Med; 1992 Apr; 116(8):624-9. PubMed ID: 1546861
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid therapy in hepatobiliary disease.
Kowdley KV
Am J Med; 2000 Apr; 108(6):481-6. PubMed ID: 10781781
[TBL] [Abstract][Full Text] [Related]
16. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Holtmeier J; Leuschner U
Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease.
Lirussi F; Beccarello A; Bortolato L; Morselli-Labate AM; Crovatto M; Ceselli S; Santini G; Crepaldi G
Liver; 1999 Oct; 19(5):381-8. PubMed ID: 10533795
[TBL] [Abstract][Full Text] [Related]
18. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group.
Kanamaru A; Takemoto Y; Kakishita E; Dohy H; Kodera Y; Moriyama Y; Shibata A; Kasai M; Katoh S; Saitoh H
Bone Marrow Transplant; 1995 Jun; 15(6):885-9. PubMed ID: 7581086
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid.
Assy N; Adams PC; Myers P; Simon V; Minuk GY; Wall W; Ghent CN
Transplantation; 2007 Jun; 83(12):1571-6. PubMed ID: 17589339
[TBL] [Abstract][Full Text] [Related]
20. Vanishing bile duct syndrome after allogeneic bone marrow transplantation: is it the end of the road?
Bakanay ŞM; Bilgin AU; Bektaş M; Idilman R; Erden E; Arat M; Arslan Ö
Turk J Gastroenterol; 2013; 24(4):359-62. PubMed ID: 24254270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
